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Table 4
Genotypes and Western Blot Analysis of the PCCB-Deficient Patients
Patient(s) Mutationsa Western Blotb Origin (n)
ALT, CBV, MRA, LMC, DTV ins/del / ins/del  Spain (3), Chile (2)
SSL, APJ c1170insT / c1170insT  Spain (2)
PRG, NGA E168K / E168K c Spain (1), Chile (1)
SVL A497V / A497V c Spain (1)
CTGd G198D / G198D NS Spain (1)
LGA, JGG, FM ins/del / E168K c Spain (2), Chile (1)
VMP ins/del / A497V c Spain (1)
AJA ins/del / R44P c Spain (1)
AG ins/del / W531X c Spain (1)
EAC ins/del / R512C  Spain (1)
PPM ins/del / R165W c Ecuador (1)
PVD ins/del / G131R c Spain (1)
DMS, HMM c1170insT / E168K c Spain (1), Chile (1)
PHH c1170insT / L519P  Spain (1)
CJF A497V / S106R NS Spain (1)
MBG E168K / IVS13GrC c Spain (1)
OVEe R410W / IVS10–11del6 f Spain (1)
HM R410W / ND f Brazil (1)
LVA c1170insT / ND NS Spain (1)
MV ins/del / 1298–1299insA  Chile (1)
a ND  not detected.
b A plus sign () indicates the presence of the b-subunit, and a minus sign () indicates the
absence of the b-subunit. NS  not studied (fibroblasts not available).
c Two bands of b-PCC of normal and reduced size.
d Clinical report was published in the article by Del Valle et al. (1982).
e Clinical report was published in the article by Pe´rez-Cerda´ et al. (1998).
f b-PCC smaller than normal size.
In the August 1998 issue of the Journal, several errors
appeared in the article “Human Propionyl-CoA Car-
boxylase b Subunit Gene: Exon-Intron Definition and
Mutation Spectrum in Spanish and Latin American Pro-
pionic Acidemia Patients, ” by Rodrı´guez-Pombo et al.
(63:360–369). The corrected table is shown below (the
changes are within the boxes). Correspondingly, in the
Results section, the sentence that begins in the second
line of page 367 should read as follows: “The results
indicated a total absence of immunoreactive b-PCC in
all patients carrying the mutations ins/del or c1170instT
in homozygous fashion and in those patients who were
compound heterozygotes for the ins/del and
1298–1299insA, ins/del and R512C, or c1170insT and
L519P mutations.” In the Discussion section, the final
sentence in the third paragraph (right-hand column on
p. 367) should read as follows: “The total absence of
immunoreactive protein observed in the western blot of
patients who carry R512C or L519P in combination
with mutations producing undetectable levels of b-PCC,
such as ins/del or c1170insT, supports the hypothesis
that certain point mutations can be severe with regard
to protein stability.”
